UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 24, 2003
ATHEROGENICS, INC.
| Georgia | 0-31261 | 58-2108232 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)
Registrant’s telephone number, including area code (678) 336-2500
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 PRESS RELEASE DATED 7/24/03 | ||||||||
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
Exhibits.
See Exhibit Index attached to this current report on Form 8-K.
Item 9. Regulation FD Disclosure (furnished pursuant to Item 12, “Results of Operations and Financial Condition.”)
On July 24, 2003, AtheroGenics, Inc. issued a press release to report the company’s financial results for the quarter ended June 30, 2003. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| ATHEROGENICS, INC | ||
| Date: July 24, 2003 | /s/ MARK P. COLONNESE | |
|
|
||
|
Mark P. Colonnese Senior Vice President of Finance and Administration and Chief Financial Officer |
3
EXHIBIT INDEX
The following exhibit is furnished as part of this current report on Form 8-K.
| Exhibit No. | Description | |||
| 99.1 | – | Press Release dated July 24, 2003 |
4